Side-by-side comparison of AI visibility scores, market position, and capabilities
Caris Life Sciences provides comprehensive molecular profiling of tumors to guide cancer treatment decisions, with one of the largest oncology biomarker databases.
Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized cancer treatments. The company's flagship test Molecular Intelligence analyzes tumors using whole transcriptome sequencing, whole exome sequencing, and protein expression to identify biomarkers that predict response to specific therapies including targeted drugs and immunotherapies. Caris has built one of the largest real-world oncology molecular databases, with profiles from hundreds of thousands of patient tumors that are used for research, drug development partnerships, and AI model training. The company serves oncologists, cancer centers, and pharmaceutical companies conducting biomarker-driven clinical trials. Caris has raised over $1B and operates CLIA-certified laboratory facilities in Phoenix and Irving. The company's database and AI capabilities have attracted partnerships with pharmaceutical companies seeking to identify patient populations most likely to respond to novel therapies. Caris positions itself at the intersection of clinical diagnostics and drug development infrastructure, generating value both from patient care and from the insights its large clinical database enables.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
Caris Life Sciences vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.